slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 91,651-91,680
Pages 3,683
Rows per page 30
Component
91,651-91,680 of 110,471
43
The slide uses a bulleted list to define the therapeutic rationale and two line charts to provide empirical evidence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
55
The slide uses four dose-response curves to show cytotoxicity against different target copy numbers.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
56
The chart uses a broken x-axis between -29 and 0. The legend indicates four distinct treatment groups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
57
The slide uses a log-linear plot to demonstrate drug clearance over time.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
61
The funnel is represented as a series of concentric circles/segments.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
65
The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
66
The slide highlights the breadth of the company's intellectual property protection across major global regions.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
74
Data cut-off Sep 30, 2023. N=28 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
07
Uses a hub-and-spoke diagram to illustrate the central problem of neurotoxicity and its four primary negative consequences.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
16
Includes comparative bar charts for transduction efficiency and toxicity markers, and flow cytometry data for anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
17
The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
03
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
17
The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
20
The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
25
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
50
The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
55
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit